History

Developed by Novo Nordisk in Denmark as a once-weekly successor to liraglutide; chemists Jesper Lau, Thomas Kruse, and Paw Bloch are credited with the molecule, described in a 2015 paper. It attaches a fatty-acid chain to GLP-1 so it binds albumin and resists breakdown. The FDA approved injectable Ozempic for type 2 diabetes in December 2017, oral Rybelsus in 2019, and higher-dose Wegovy for weight management in June 2021.

Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most compounds we profile, the human evidence here is large, long, and consistent — so the honest job is to describe where it holds up and where it does not.

What it is

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist: a modified version of a gut hormone the body releases after eating. By activating GLP-1 receptors in the pancreas, gut, and brain, it increases insulin release when blood sugar is high, slows stomach emptying, and reduces appetite. It is sold as Ozempic (weekly injection for type 2 diabetes), Wegovy (higher-dose weekly injection for weight management), and Rybelsus (a daily tablet for diabetes). In January 2026, the FDA also approved an oral tablet form of Wegovy for chronic weight management — the first oral GLP-1 cleared for that use.

The claims

The mainstream claims are straightforward: meaningful weight loss, better blood-sugar control in type 2 diabetes, and reduced risk of heart attack and stroke in certain patients. Off-label and online, it is also promoted for cosmetic weight loss in people who are not obese, and increasingly for conditions like addiction — claims that are far less settled.

What the evidence actually shows

The core claims are backed by large randomized controlled trials, not anecdote.

Weight: In the STEP 1 trial (Wilding et al., NEJM 2021; ~1,960 adults without diabetes), weekly 2.4 mg semaglutide produced about 14.9% mean weight loss over 68 weeks versus 2.4% on placebo, alongside diet and exercise.
Blood sugar: The SUSTAIN program established meaningful HbA1c and weight reductions in type 2 diabetes, supporting the original Ozempic approval.
Heart outcomes: The SELECT trial (17,604 adults with established cardiovascular disease and overweight/obesity, without diabetes) found a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death; HR 0.80) over a mean of about four years.

Two honest caveats. First, benefits depend on continued use — weight tends to return after stopping. Second, the cardiovascular evidence is strongest in people who already have heart disease plus excess weight; it does not automatically extend to healthy people using the drug cosmetically.

Legal and regulatory status

Semaglutide is an FDA-approved prescription drug, not a supplement or research chemical. Approved uses include type 2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy, now in both injectable and oral tablet form), and reducing cardiovascular risk in adults with established heart disease plus overweight or obesity (Wegovy, approved March 2024). For athletes: semaglutide is not banned under the 2026 WADA Prohibited List, but it has been on WADA’s Monitoring Program since 2024, meaning use is being tracked and its status could change in future updates.

Safety

The most common effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — usually worst when increasing the dose. Less common but documented risks include gallbladder disease/gallstones and, less often, pancreatitis. It carries a boxed warning for thyroid C-cell tumors based on rodent studies, and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2; whether it causes these tumors in humans is not known, and a clear human cancer signal has not been established. Substantial weight loss also includes loss of lean muscle mass, which resistance training and adequate protein may partly offset. This is not medical advice — these drugs require prescription and monitoring.

Bottom line

Semaglutide is a genuinely effective drug for weight loss, glycemic control, and cardiovascular risk reduction in the studied populations, with risks that are real but generally manageable under medical supervision. The evidence is unusually robust — the open questions are mostly about long-term use, durability after stopping, and use in people outside the trial populations.

Evidence grade: Strong human.

Semaglutide (Ozempic / Wegovy): An Evidence Review